Table 1.
Summary of baseline demographic, disease activity and comorbidity data for controls and patients
| Variable | Controls n=30 | All patients with ERA n=81 | ETN-MTX n=40 | MTX-TT n=41 |
| Demographics* | ||||
| Female % (n/N) | 63 (19/30) | 69 (55/81) | 60 (24/40) | 76 (31/41) |
| Age, years median (IQR) | 54 (23) | 51 (21) | 48.5 (13.5) | 54 (23) |
| BMI, median (IQR) | 27.0 (7.1) | 24.9 (5.4) | 25.6 (5.5) | 24.6 (5.2) |
| RA profile, % (n/N) | ||||
| CCP positive | N/A | 84 (64/76) | 82 (31/38) | 87 (33/38) |
| RF positive | N/A | 75 (57/76) | 68 (26/38) | 82 (31/38) |
| RA disease activity profile, median (IQR) | n=77 | n=39 | n=38 | |
| Baseline DAS28 score | N/A | 5.3 (1.4) | 5.5 (1.6) | 5.3 (1.4) |
| ESR | N/A | 30 (30) | 31 (33.5) | 30 (28.3) |
| CRP | N/A | 8 (23) | 8 (27) | 8 (17.8) |
| Traditional CV risk factors, % (n/N; unless otherwise stated) | ||||
| Hypertension | N/A | 7 (6/81) | 3 (1/40) | 12 (5/41) |
| Hypercholesterolaemia | N/A | 2 (2/81) | 0 (0/40) | 5 (2/41) |
| Diabetes | 0 (0/30) | 0 (0/81) | 0 (0/40) | 0 (0/41) |
| Family history IHD | N/A | 5 (4/81) | 5 (2/40) | 5 (2/41) |
| Systolic blood pressure, mm Hg median (IQR) | 120.5 (13.5) | 121 (26) | 122 (24.5) | 120 (23) |
| Pack years smoking, years median (IQR) | 0 (0.4) | 0.1 (10) | 0 (5.3) | 3 (17.5) |
| Smoking status | n=30 | n=76 | n=38 | n=38 |
| Current | 13 (4/30) | 22 (17) | 16 (6) | 29 (11) |
| Former | 17 (5/30) | 33 (25) | 29 (11) | 37 (14) |
| Never | 70 (21/30) | 45 (34) | 55 (21) | 34 (13) |
*Denominator that is less than n=81 indicates missing data (not retrieved as original imputation model included gender).
BMI, body mass index; CCP, cyclic-citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score-28; ERA, early rheumatoid arthritis; ESR, erythrocyte sedimentation rate; ETN, etanercept; IHD, ischaemic heart disease; MTX, methotrexate; NA, not applicable; RF, rheumatoid factor; TA1, immediate ETN and MTX treatment; TA2, first-line MTX±additional csDMARD.